JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2022, 71(3):91-97 | DOI: 10.5817/CSF2022-3-91

Metronomic therapy in the treatment of cancer

Dana Mazánková1,*, Veronika Bárková2, Pavel Mazánek3
1 Masarykova univerzita, Farmaceutická fakulta, Ústav aplikované farmacie, Brno
2 Oddělení klinické farmacie, Nemocniční lékárna FN u svaté Anny v Brně
3 Klinika dětské onkologie Lékařské fakulty Masarykovy univerzity, Oddělení dětské hematologie a biochemie Fakultní nemocnice Brno

Metronomic therapy is a therapeutic method in selected oncological diseases, using long-term administration of low doses of drugs with direct or indirect antitumor effect. In addition, to direct cytotoxic eradication of tumor cells, metronomic therapy can very strongly affect the tumor microenvironment; it also has an immunomodulatory and antiangiogenic effect. Its minimal toxic profile allows for use in patients with severe organ dysfunctions and directly impacts the quality of life and social inclusion of oncological patients.

Keywords: toxicity; resistance; metronomic therapy; antiangiogenic effect; immunomodulatory effect

Received: February 24, 2022; Accepted: April 27, 2022; Published: March 1, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mazánková D, Bárková V, Mazánek P. Metronomic therapy in the treatment of cancer. Čes. slov. farm. 2022;71(3):91-97. doi: 10.5817/CSF2022-3-91.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Scharovsky O. G., Mainetti L., Rozados V. Metronomic chemotherapy: changing the paradigm that more is better. Current Oncol. 2009; 16(2), 7-15. doi: 10.3747/co.v16i2.420. ISSN 1198-0052 Go to original source... Go to PubMed...
    2. Hanah D., Bergers G., Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Investig. 2000; 105(8), 1045-1047. doi: 10.1172/JCI9872. ISSN 0021-9738. Go to original source... Go to PubMed...
    3. Browder T., Butterfield C. E., Brigit M., Shi B., Marshall B., O'Reilly M. S., Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000; 60(7), 1878-1886.
    4. Kareva I., Waxman D. J., Klement G. L. Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett. 2015; 358(2), 100-106. doi: 10.1016/j.canlet.2014.12.039 Go to original source... Go to PubMed...
    5. Maiti R. Metronomic chemotherapy. J. Pharmacol. Pharmacotherapeutics 2014; 5(3), 186-192. doi: 10.4103/0976-500X.136098. ISSN 0976-500X. Go to original source... Go to PubMed...
    6. Pramanik R., Bakhshi S. Metronomic therapy in pediatric oncology: A snapshot. Pediat. Blood and Cancer 2019; 66(9), 1-12. doi: 10.1002/pbc.27811. Go to original source... Go to PubMed...
    7. Bronišová D., Múdry P., Štěrba J., Bajčiová V., Valík D., Dubská L., Mazánek P., Lokaj P., Zitterbart K. Metronomická léčba v onkologii jako nová léčebná metoda. Onkologie 2009; 3(4), 227-229.
    8. Klener P. Angiogeneze a nádorová onemocnění. Remedia 2002; 12(1), 2-8.
    9. Folkman J. Tumor angiogenesis: therapeutic implications. NEJM 1971; 285(21), 1182-1186. doi: 10.1056/NEJM197111182852108 Go to original source... Go to PubMed...
    10. Chen H., Herndon M. E., Lawler J. The cell biology of thrombospondin-1. Matrix biology: journal of the International Society for Matrix Biol. 2000; 19(7), 597- 614. doi: 10.1016/s0945-053x(00)00107-4. ISSN 0945- 053X Go to original source... Go to PubMed...
    11. de Fraipont F., Nicholson A. C., Feige J. J., Van Meir E. G. Thrombospondins and tumor angiogenesis. Trends Mol. Med. 2001; 7(9), 401-407. doi: 10.1016/s1471-4914(01)02102-5 Go to original source... Go to PubMed...
    12. Lawler J. Thrombospondin-1 as an Endogenous Inhibitor of Angiogenesis and Tumor Growth. J. Cell. Mol. Med. 2002; 6 (1), 1-12. doi: 10.1111/j.1582-4934.2002.tb00307.x Go to original source... Go to PubMed...
    13. Bocci G., Francia G., Man S., Lawler J., Kerbler R. S. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. PNAS 2003; 100(22), 12917-12922. doi: 10.1073/pnas.2135406100 Go to original source... Go to PubMed...
    14. Bertolini F., Paul S., Mancuso P., Monestiroli S., Gobbi A., Shaked Y., Kerbel R. S. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003; 63(15), 4342-4346.
    15. Asahara T., Takahashi T., Masuda H., Kalka C., Chen D., Iwaguro H., Inai Y., Silver M., Iner J. M. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999; 18(14), 3964-3972. doi: 10.1093/emboj/18.14.3964 Go to original source... Go to PubMed...
    16. Kerbel R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioassays 1991; 13(1), 31-36. doi: 10.1002/bies.950130106 Go to original source... Go to PubMed...
    17. Riesco-Martinez M., Parra K., Saluja R., Francia G., Emmenegger U. Resistance to metronomic chemotherapy and ways to overcome it. Cancer Lett. 2017; 400, 311-318. doi: 10.1016/j.canlet.2017.02.027 Go to original source... Go to PubMed...
    18. Shu-Ting P., Zhi-Ling L., Zhi-Xu H., Jia-Xuan Q., Shu- -Feng Z. Molecular mechanisms for tumour resistance to chemotherapy. Clin. Exp. Pharmacol. Physiol. 2016; 43(8), 723-737. doi: 10.1111/1440-1681.12581 Go to original source... Go to PubMed...
    19. Mross K., Steinbild S. Metronomic anti-cancer therapy - an ongoing treatment option for advanced cancer patients. J. Cancer Therap. Res. 2012; 1(1). doi: 10.7243/2049-7962-1-32 Go to original source...
    20. Koki A. T., Masferrer J. L. Celecoxib: A Specific COX - 2 Inhibitor With Anticancer Properties. Cancer Control 2002; 9(2), 28-35. doi: 10.1177/107327480200902S04 Go to original source... Go to PubMed...
    21. Shim J. S., Matsui Y., Bhat S., Nacev B. A., Xu J., Bhang H. C., Dhara S., Han K. Ch., Chong C. R., Pomper M. G., SO A., Liu J. O. Effect of Nitroxoline on Angiogenesis and Growth of Human Bladder Cancer. JNCI 2010; 102(24), 1855-1873. doi: 10.1093/jnci/djq457 Go to original source... Go to PubMed...
    22. Shichiri M., Fukai N., Kono Y., Tanaka Y. Rifampicin as an Oral Angiogenesis Inhibitor Targeting Hepatic Cancers. Cancer Res. 2009; 69(11), 4760-4768. doi: 10.1158/0008-5472.CAN-08-3417 Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.